Icagen/J&J Sickle Cell Disease Treatment Hits Phase III Snag
An independent data monitoring committee recommends Phase III enrollment continue for ICA-17043, but only for patients on concurrent hydroxyurea therapy.
An independent data monitoring committee recommends Phase III enrollment continue for ICA-17043, but only for patients on concurrent hydroxyurea therapy.